Shaneda Warren Andersen

Dr. Shaneda Warren Andersen


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2019 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
SAShaneda Warren Andersen
Shaneda Warren Andersen
WBWilliam J. Blot
William J. Blot
LLLoren Lipworth
Loren Lipworth
MSMark Steinwandel
Mark Steinwandel
HMHarvey J. Murff
Harvey J. Murff
WZWei Zheng
Wei Zheng
Colorectal cancer (CRC) is the fourth most commonly diagnosed cancer in the United States and second-leading cause of cancer death.1 Colorectal cancer outcomes vary by race and socioeconomic status (SES), with African American individuals and individuals with low SES having higher incidence and mortality than other groups. Most CRCs arise from noncancerous, adenomatous polyps.2 Colorectal cancer screening programs aim to intervene in the cancer progression process by the detection and subsequent removal of polyps before they progress to cancer and by early detection of CRCs in asymptomatic individuals. The importance of CRC screening by visual- and stool-based screening modalities for reducing CRC incidence and mortality has been demonstrated in randomized clinical trials and cohort studies.3-8 Cohort studies provide opportunities to evaluate the effectiveness of CRC screening in targeted populations. A previous cohort study5 of data from follow-up of nurses and other health care professionals reported 40% to 56% lower CRC incidence among participants screened through lower endoscopy (colonoscopy or sigmoidoscopy) compared with participants who had never undergone lower endoscopy screening, and a 68% reduction in colorectal cancer mortality among participants who had undergone screening colonoscopy. Stool-based screening programs, such as fecal occult blood tests (FOBTs) and fecal immunochemical tests, have also been shown to be effective for detecting colorectal polyps and cancers.8 Randomized clinical trials of stool-based screening modalities have found reduced CRC incidence and mortality among patients with abnormal stool-based screening findings who underwent diagnostic colonoscopy and polypectomy.8,9

1 November 2023 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
TLThomas Lawler
Thomas Lawler
ZWZoe L. Walts
Zoe L. Walts
MSMark Steinwandel
Mark Steinwandel
LLLoren Lipworth
Loren Lipworth
HMHarvey J. Murff
Harvey J. Murff
SAShaneda Warren Andersen
Shaneda Warren Andersen
Type 2 diabetes is a condition of progressive insulin dysregulation, typically occurring alongside metabolic dysfunctions including hyperglycemia and hyperinsulinemia.1 In the US, an estimated 37.3 million people have diabetes, as indicated by abnormal fasting plasma glucose or hemoglobin A1c (HbA1c).2 Black adults have a disproportionate diabetes burden, with an age-adjusted prevalence of 16.8% (95% CI, 15.3-18.5) compared with 11.2% (95% CI, 9.5-13.2) in White adults.2 Both prevalence3,4 and incidence5 of diabetes are rising more in Black than White adults, suggesting widening racial disparities. Socioeconomic disparities by both education and household income are also evident.2,4

26 April 2024 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
TLThomas Lawler
Thomas Lawler
LPLisa Parlato
Lisa Parlato
SAShaneda Warren Andersen
Shaneda Warren Andersen
Background: Early-onset colorectal cancer (CRC), defined as diagnosis before age 50, has increased in recent decades. Although more often diagnosed at advanced stage, associations with other histological and molecular markers that impact prognosis and treatment remain to be clarified. We conducted a systematic review and meta-analysis concerning the prevalence of prognostic and predictive tumor markers for early- vs. late-onset CRC, including oncogene mutations, microsatellite instability (MSI), and emerging markers including immune cells and the consensus molecular subtypes.Methods: We systematically searched PubMed for original research articles published between April 2013–January 2024. Included studies compared the prevalence of tumor markers in early- vs. late-onset CRC. A meta-analysis was completed and summary odds ratios (ORs) with 95% confidence intervals (CIs) were obtained from a random effects model via inverse variance weighting. A sensitivity analysis was completed to restrict the meta-analysis to studies that excluded individuals with Lynch syndrome, a hereditary condition that influences the distribution of tumor markers for early-onset CRC.Results: In total, 149 articles were identified. Tumors from early-onset CRC are less likely to include mutations in KRAS (OR, 95% CI: 0.91, 0.85-0.98), BRAF (0.63, 0.51-0.78), APC (0.70, 0.58-0.84), and NRAS (0.88, 0.78-1.00) but more likely to include mutations in PTEN (1.68, 1.04-2.73) and TP53 (1.34, 1.24-1.45). After limiting to studies that excluded Lynch syndrome, the associations between early-onset CRC and BRAF (0.77, 0.64-0.92) and APC mutation (0.81, 0.67-0.97) were attenuated, while an inverse association with PIK3CA mutation was also observed (0.88, 0.78-0.99). Early-onset tumors are less likely to develop along the CpG Island Methylator Phenotype pathway (0.24, 0.10-0.57), but more likely to possess adverse histological features including high tumor grade (1.20, 1.15-1.25), and mucinous (1.22, 1.16-1.27) or signet ring histology (2.32, 2.08-2.57). A positive association with MSI status (1.31, 1.11-1.56) was also identified. Associations with immune markers and the consensus molecular subtypes are inconsistent.Discussion: A lower prevalence of mutations in KRAS and BRAF is consistent with extended survival and superior response to targeted therapies for metastatic disease. Conversely, early-onset CRC is associated with aggressive histological subtypes and TP53 and PTEN mutations, which may serve as therapeutic targets.

13 January 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
TLThomas Lawler
Thomas Lawler
SAShaneda Warren Andersen
Shaneda Warren Andersen
Epidemiological studies suggest that higher serum 25-hydroxyvitamin D is associated with lower risk for several cancers, including breast, prostate, colorectal, and lung cancers. To mitigate confounding, genetic instrumental variables (IVs) have been used to estimate causal associations between 25-hydroxivtamin D and cancer risk via Mendelian randomization (MR). We provide a systematic review of 31 MR studies concerning 25-hydroxyvitamin D and cancer incidence and mortality identified from biomedical databases. MR analyses were conducted almost exclusively in European-ancestry populations and identified no statistically significant associations between higher genetically predicted 25-hydroxyvitamin D and lower risk for total cancer or colorectal, breast, prostate, lung, or pancreatic cancers. In recent studies including ≥80 genetic IVs for 25-hydroxyvitamin D, null associations were reported for total cancer (odds ratio [95% confidence interval] per 1-standard deviation increase: 0.98 [0.93–1.04]), breast (1.00 [0.98–1.02]), colorectal (0.97 [0.88–1.07]), prostate (0.99 [0.98–1.01]), and lung cancer (1.00 [0.93–1.03]). A protective association was observed for ovarian cancer in the Ovarian Cancer Association Consortium (0.78 [0.63–0.96] per 20 nmol/L increase, p-trend = 0.03), but not in the UK Biobank (1.10 [0.80–1.51]). Null associations were reported for other tumor sites (bladder, endometrium, uterus, esophagus, oral cavity and pharynx, kidney, liver, thyroid, or neural cells). An inconsistent protective association for cancer-specific mortality was also observed. Results from MR analyses do not support causal associations between 25-hydroxyvitamin D and risk for cancer incidence or mortality. Studies including non-White populations may be valuable to understand low 25-hydroxyvitamin D as a modifiable risk factor in populations with a higher risk of common cancers, including African ancestry individuals.

19 July 2011 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
SAShaneda Warren Andersen
Shaneda Warren Andersen
PNP. A. Newcomb
P. A. Newcomb
JHJ. M. Hampton
J. M. Hampton
LTL. Titus-Ernstoff
L. Titus-Ernstoff
KEK. M. Egan
K. M. Egan
ATA. Trentham-Dietz
A. Trentham-Dietz

9 September 2023 in Cancer Causes & Control
Verified
Journal Article
Closed access
PDF file
TLThomas Lawler
Thomas Lawler
LPLisa Parlato
Lisa Parlato
SAShaneda Warren Andersen
Shaneda Warren Andersen